Administration of MDP, a NOD2 agonist, increases antitumor immunity to PD-1/PD-L1 blockade (7), and using blocking antibodies against PD-L2/RGMb overcomes microbiome-mediated resistance in multiple mouse tumor models (8). This evidence concerns the gene PDCD1 and neoplasm.